


ABSTRACT

The present invention relates to new piperidyl- or piperazinyl-substituted indan derivatives having the formula I



(I)

wherein

X is N or CH;

Y is NR_2CH_2 , CH_2NR_2 , NR_2CO , CONR_2 or NR_2SO_2

wherein R_2 is H or $\text{C}_1\text{-C}_6$ alkyl;

R_1 is H, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_6$ cycloalkyl;

R_3 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl or $(\text{CH}_2)_n\text{-aryl}$, wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted;

n is 0-4;

R_9 is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, OCF_3 , OCHF_2 , OCH_2F , halogen, CN, CF_3 , OH, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_1\text{-C}_6$ alkoxy- $\text{C}_1\text{-C}_6$ alkyl, NR_6R_7 , SO_3CH_3 , SO_3CF_3 , $\text{SO}_2\text{NR}_6\text{R}_7$, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) $\text{C}_1\text{-C}_6$ alkyl; or

COR_8 ; wherein R_6 , R_7 and R_8 are as defined above,

as (*R*)- enantiomers, (*S*)-enantiomers or racemates in the form of a free base or pharmaceutically acceptable salts or solvates thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds in therapy.